electroCore, Inc. (NASDAQ:ECOR) Short Interest Up 20.1% in August

electroCore, Inc. (NASDAQ:ECOR) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totalling 18,500 shares, a growth of 20.1% from the July 31st total of 15,400 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average trading volume of 7,800 shares, the short-interest ratio is currently 2.4 days.

Insider Buying and Selling at electroCore

In other electroCore news, CEO Daniel S. Goldberger bought 38,505 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were purchased at an average price of $6.43 per share, with a total value of $247,587.15. Following the purchase, the chief executive officer now directly owns 249,565 shares of the company’s stock, valued at $1,604,702.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Thomas J. Errico bought 5,000 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were bought at an average cost of $6.12 per share, with a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 233,818 shares of the company’s stock, valued at $1,430,966.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel S. Goldberger bought 38,505 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were bought at an average cost of $6.43 per share, for a total transaction of $247,587.15. Following the completion of the transaction, the chief executive officer now directly owns 249,565 shares of the company’s stock, valued at $1,604,702.95. The disclosure for this purchase can be found here. Insiders have acquired 44,505 shares of company stock valued at $284,617 in the last quarter. Corporate insiders own 13.14% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. PFG Investments LLC acquired a new position in shares of electroCore during the 1st quarter worth about $111,000. International Assets Investment Management LLC raised its holdings in electroCore by 49.8% in the 1st quarter. International Assets Investment Management LLC now owns 53,020 shares of the company’s stock valued at $324,000 after acquiring an additional 17,620 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after acquiring an additional 2,270 shares in the last quarter. Hedge funds and other institutional investors own 26.74% of the company’s stock.

electroCore Trading Up 0.8 %

Shares of ECOR stock opened at $6.05 on Friday. electroCore has a 1-year low of $4.89 and a 1-year high of $8.08. The company has a market capitalization of $36.34 million, a price-to-earnings ratio of -2.12 and a beta of 0.55. The stock’s fifty day simple moving average is $6.13 and its 200-day simple moving average is $6.34.

electroCore (NASDAQ:ECOR) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. electroCore had a negative return on equity of 219.33% and a negative net margin of 88.12%. The business had revenue of $6.14 million for the quarter, compared to the consensus estimate of $5.85 million. During the same quarter in the previous year, the company posted ($1.03) earnings per share. On average, sell-side analysts predict that electroCore will post -1.38 EPS for the current year.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.